In pooled analyses of patients, voriconazole was shown to be effective against the following additional fungal pathogens:
Scedosporium apiospermum — Successful response to voriconazole therapy was seen in 15 of 24 patients (63%). Three of these patients relapsed within 4 weeks, including 1 patient with pulmonary, skin and eye infections, 1 patient with cerebral disease, and 1 patient with skin infection. Ten patients had evidence of cerebral disease and 6 of these had a successful outcome (1 relapse). In addition, a successful response was seen in 1 of 3 patients with mixed organism infections.
Fusarium spp.- Nine of 21 (43%) patients were successfully treated with voriconazole. Of these 9 patients, 3 had eye infections, 1 had an eye and blood infection, 1 had a skin infection, 1 had a blood infection alone, 2 had sinus infections, and 1 had disseminated infection (pulmonary, skin, hepatosplenic). Three of these patients (1 with disseminated disease, 1 with an eye infection and 1 with a blood infection) had Fusarium solani and were complete successes. Two of these patients relapsed, 1 with a sinus infection and profound neutropenia and 1 post surgical patient with blood and eye infections.
A total of 22 patients aged 12 to 18 years with IA were included in the adult therapeutic studies. Twelve out of 22 (55%) patients had successful response after treatment with a maintenance dose of voriconazole 4 mg/kg every 12 hours.
Additional pediatric use information is approved for PF PRISM C.V.’s VFEND (voriconazole). However, due to PF PRISMC.V.’s marketing exclusivity rights, this drug product is not labeled with that information .
Click here to enter How Supplied
Voriconazole tablets, 50 mg are white to off-white, round, biconvex film coated tablets debossed with “283” on one side and “S” on the other side.
Voriconazole tablets, 200 mg are white to off-white, capsule shaped, biconvex film coated tablets debossed with “285” on one side and “S” on the other side.
NDC 50268-803-12 (10 tablets per card, 2 cards per card).
Dispensed in Unit Dose Package. For Institutional Use Only.
Voriconazole tablets should be stored at 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Advise the patient to read the FDA-Approved Patient Labeling (Patient Information).
• Advise female patients of the potential risks to a fetus.
• Advise females of reproductive potential to use effective contraception during treatment with voriconazole tablets.
Pulaski, TN 38478
Mfg. Rev. 03/21
AV 08/22 (P) AvPAK
|VORICONAZOLE voriconazole tablet, coated|
|Labeler — AvPAK (832926666)|
Revised: 08/2022 AvPAK
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.